文献速递心力衰竭与心肌病

门诊心衰患者药物剂量与生存的性别差异

Heart failure medication dosage and survival in women and men seen at outpatient clinics.
PubMed 文献 · Heart · 2021-07-14

该研究基于荷兰13家门诊心内科电子健康记录,分析561名女性和615名男性的心衰用药剂量与生存关系。中位随访3.7年,252例死亡;两性平均目标剂量在ACEI/ARB和β受体阻滞剂均为50%,MRA为100%。女性HFrEF中ACEI/ARB剂量<50%与较低死亡率相关,男性无此关联,HFpEF中未观察到此现象。

要点

  • 门诊心衰患者平均接受指南推荐剂量的一半。
  • 女性HFrEF中ACEI/ARB剂量<50%与较低死亡率相关。
  • β受体阻滞剂剂量与全因死亡率无关。

核心结论

  • 门诊心衰患者接受指南推荐剂量的一半,女性HFrEF中较低ACEI/ARB剂量与改善生存相关。

研究设计与样本

  • 从荷兰13家门诊心内科诊所提取电子健康记录,纳入接受至少一种指南推荐心衰药物的患者,共561名女性和615名男性。

主要发现

  • 中位随访3.7年,252例死亡(48%女性;167例HFrEF,84例HFpEF)。
  • 两性平均目标剂量在ACEI/ARB和β受体阻滞剂均为50%,MRA为100%。
  • 女性HFrEF中ACEI/ARB剂量<50%与较低死亡率相关,男性无此关联,HFpEF中未观察到此现象。
  • β受体阻滞剂剂量与全因死亡率无关。

关键数值与推荐

  • ACEI/ARB剂量<50%目标剂量与女性HFrEF较低死亡率相关(参考剂量≥50%目标剂量)。
  • β受体阻滞剂剂量与全因死亡率无关联。
  • MRA平均目标剂量为100%。

临床怎么用

  • 门诊心衰患者实际用药剂量常为指南推荐的一半,需关注性别差异优化治疗。
  • 女性HFrEF患者使用较低ACEI/ARB剂量可能与改善生存相关,支持重新定义女性最佳药物治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Women with heart failure with reduced ejection fraction (HFrEF) may reach optimal treatment effect at half of the guideline-recommended medication dose. This study investigates prescription practice and its relation with survival of patients with HF in daily care. METHODS: Electronic health record data from 13 Dutch outpatient cardiology clinics were extracted for HF receiving at least one guideline-recommended HF medication. Dose changes over consecutive prescriptions were modelled using natural cubic splines. Inverse probability-weighted Cox regression was used to assess the relationship between dose (reference≥50% target dose) and all-cause mortality. RESULTS: The study population comprised 561 women (29% HFrEF (ejection fraction (EF)<40%), 49% heart failure with preserved ejection fraction (EF≥50%); HFpEF and 615 men (47% and 25%, respectively). During a median follow-up of 3.7 years, 252 patients died (48% women; 167 HFrEF, 84 HFpEF). Nine hundred thirty-four patients (46% women) received ACE inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), 795 (48% women) beta blockers and 178 (42% women) mineralocorticoid receptor antagonists (MRAs). In both sexes, the mean target dose across prescriptions was 50% for ACEI/ARBs and beta blockers, and 100% for MRAs. ACEI/ARB dose of <50% was associated with lower mortality in women but not in men with HFrEF. This was not seen in patients with HFpEF. Beta-blocker dose was not associated with all-cause mortality. CONCLUSION: Patients with HF seen in outpatient cardiology clinics receive half of the guideline-recommended medication dose. Lower ACEI/ARB dose was associated with improved survival in women with HFrEF. These results underscore the importance of (re)defining optimal medical therapy for women with HFrEF.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Bots SH, Onland-Moret NC, Tulevski II, et al. Heart failure medication dosage and survival in women and men seen at outpatient clinics. Heart. 2021. PMID: 34261736. doi:10.1136/heartjnl-2021-319229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。